Affiliation:
1. GOVERNMENT INSTITUTION “L.T.MALAYA THERAPY NATIONAL INSTITUTE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE”, KHARKIV, UKRAINE
Abstract
The aim: The aim is to study the effect of β-ABs in patients with LT3S on the course of HF.
Materials and methods: 354 patients with HF on a background of post-infarction cardiosclerosis were included in the 2-yeared follow-up study. LT3S was diagnosed at 89
(25.1%) patients. The levels of thyroid-stimulating hormone, free T3f and T4f, and reversible T3 were determined. The echocardioscopy was performed.
Results: Patients with HF in combination with LT3S have a heavier functional class by NYHA, greater dilatation of the left heart cavities, less myocardial contractility, a higher
frequency of atrial fibrillation and re-hospitalization. The use of β-ABs in patients with HF without LT3S leads to a likely decrease in hospitalization frequency, while in patients
with LT3S it has an opposite effect. The frequency of rehospitalization increases with an excess of β-ABs dose > 5 mg (equivalent to bisoprolol). At these patients a decrease in
serum T3 level and negative dynamics of parameters of intracardiac hemodynamics are observed.
Conclusions: The use of β-ABs in patients with LT3S leads to an increase in re-hospitalization at a dose over 5.0 mg (equivalent to bisoprolol). In these patients there is a decrease
in serum T3, an increase in T4 level; and the ejection fraction decrease; and heart cavities size increase.
Reference34 articles.
1. 1. Jabbar A., Pingitore A., Pearce S.H., Thyroid hormones and cardiovascular disease. Nat Rev Cardiol. 2017;14(1):39-55. doi: 10.1038/nrcardio.
2. 2. Arcopinto M., Cittadini A. Hormonal alterations in heart failure: anabolic impairment in chronic heart failure – diagnostic, prognostic and therapeutic issues. Front Horm Res. 2014;43:57-69. doi: 10.1159/000360559
3. 3. Fraczek M.M., Gackowski A., Przybylik-Mazurek E. et al. The relation between the low T3 syndrome in the clinical course of myocardial infarction and heart failure. Pol Merkur Lekarski. 2016;40(240):380–3.
4. 4. Economidou F., Douka E., Tzanela M. et al. Thyroid function during critical illness. Hormones (Athens). 2011;10(2):117–24.
5. 5. Wajner S.M., Maia A.L. New insights toward the acute non-thyroidal illness syndrome. Front Endocrinol (Lausanne). 2012;26:3–8.